These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 1808108)

  • 1. Renal handling and physiologic effects of the paramagnetic contrast medium, gadolinium-DOTA.
    Katzberg RW; Sahler LG; Duda SW; Morris TW; McKenna BA; Pabico RC; Niedrach WL; Tonetti FW
    Invest Radiol; 1991 Nov; 26 Suppl 1():S129-30; discussion S137-8. PubMed ID: 1808108
    [No Abstract]   [Full Text] [Related]  

  • 2. Physicochemical properties of gadoteridol and other magnetic resonance contrast agents.
    Tweedle MF
    Invest Radiol; 1992 Aug; 27 Suppl 1():S2-6. PubMed ID: 1506149
    [No Abstract]   [Full Text] [Related]  

  • 3. Subcellular localisation of gadolinium in the rat brain.
    Allard M; Kien P; Caille JM; Bonnemain B; Doucet D; Simonnet G
    J Neuroradiol; 1987; 14(2):159-62. PubMed ID: 3681416
    [No Abstract]   [Full Text] [Related]  

  • 4. In vitro and in vivo comparative performance studies of gadolinium-loaded zeolites and Gd-DOTA as contrast agents for MRI applications.
    Contro J; Silva DA; Santisteban OAN; Narayana PA; Nery JG
    J Biomed Mater Res B Appl Biomater; 2021 Aug; 109(8):1105-1115. PubMed ID: 33283412
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renal functional contrast-enhanced magnetic resonance imaging: evaluation of a new rapid-clearance blood pool agent (p792) in sprague-dawley rats.
    Mandry D; Pedersen M; Odille F; Robert P; Corot C; Felblinger J; Grenier N; Claudon M
    Invest Radiol; 2005 May; 40(5):295-305. PubMed ID: 15829826
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new biodegradable and biocompatible gadolinium (III) -polymer for liver magnetic resonance imaging contrast agent.
    Xiao Y; Xue R; You T; Li X; Pei F
    Magn Reson Imaging; 2015 Jul; 33(6):822-8. PubMed ID: 25839395
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Nephrotoxicity of contrast media in magnetic resonance tomography (MRI)].
    Heuck A; Reiser M
    Internist (Berl); 1997 Dec; 38(12):1234-5. PubMed ID: 9465330
    [No Abstract]   [Full Text] [Related]  

  • 8. Renal handling and physiologic effects of the paramagnetic contrast medium Gd-DOTA.
    Katzberg RW; Sahler LG; Duda SW; Morris TW; McKenna BA; Pabico RC; Niedrach WL; Tonetti FW
    Invest Radiol; 1990 Jun; 25(6):714-9. PubMed ID: 2354935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distribution and chemical forms of gadolinium in the brain: a review.
    Kanda T; Nakai Y; Hagiwara A; Oba H; Toyoda K; Furui S
    Br J Radiol; 2017 Nov; 90(1079):20170115. PubMed ID: 28749164
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Considerations involving paramagnetic coordination compounds as useful NMR contrast agents.
    Tweedle MF; Gaughan GT; Hagan J; Wedeking PW; Sibley P; Wilson LJ; Lee DW
    Int J Rad Appl Instrum B; 1988; 15(1):31-6. PubMed ID: 3350694
    [No Abstract]   [Full Text] [Related]  

  • 11. Physical, chemical and biological evaluations of CMD-A2-Gd-DOTA. A new paramagnetic dextran polymer.
    Corot C; Schaefer M; Beauté S; Bourrinet P; Zehaf S; Bénizé V; Sabatou M; Meyer D
    Acta Radiol Suppl; 1997; 412():91-9. PubMed ID: 9240087
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distribution profile of gadolinium in gadolinium chelate-treated renally-impaired rats: role of pharmaceutical formulation.
    Fretellier N; Salhi M; Schroeder J; Siegmund H; Chevalier T; Bruneval P; Jestin-Mayer G; Delaloge F; Factor C; Mayer JF; Fabicki JM; Robic C; Bonnemain B; Idée JM; Corot C
    Eur J Pharm Sci; 2015 May; 72():46-56. PubMed ID: 25736527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Action of gadolinium complexes on different enzyme systems.
    Allard M; Caillé JM; Bonnemain B; Meyer D; Simonnet G
    Acta Radiol Suppl; 1986; 369():572-4. PubMed ID: 2980561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gd-DTPA and Gd-DOTA effects on metabolism of glucose and phosphatidylinositols.
    Morris TW; Ekholm SE; Marinetti GV; Prentice LI; Leakey P
    Invest Radiol; 1991 Nov; 26 Suppl 1():S209-11; discussion S232-5. PubMed ID: 1808132
    [No Abstract]   [Full Text] [Related]  

  • 15. Imaging folate binding protein expression with MRI.
    Wiener EC; Konda SD; Wang S; Brechbiel M
    Acad Radiol; 2002 Aug; 9 Suppl 2():S316-9. PubMed ID: 12188260
    [No Abstract]   [Full Text] [Related]  

  • 16. Pharmacokinetics of a high-generation dendrimer-Gd-DOTA.
    Bryant LH; Jordan EK; Bulte JW; Herynek V; Frank JA
    Acad Radiol; 2002 May; 9 Suppl 1():S29-33. PubMed ID: 12019888
    [No Abstract]   [Full Text] [Related]  

  • 17. Brain distribution of MRI contrast media in rats after intracisternal injection.
    Allard M; Kien P; Caille JM; Bonnemain B; Simonnet G
    J Neuroradiol; 1987; 14(4):383-7. PubMed ID: 3131496
    [No Abstract]   [Full Text] [Related]  

  • 18. Pharmacokinetics and biodistribution study of self-assembled Gd-micelles demonstrating blood-pool contrast enhancement for MRI.
    Vorobiev V; Babič A; Crowe LA; Van De Looij Y; Lenglet S; Thomas A; Helm L; Vallée JP; Allémann E
    Int J Pharm; 2019 Sep; 568():118496. PubMed ID: 31279053
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stability of gadolinium chelates and their biological consequences: new data and some comments.
    Port M; Idee JM; Medina C; Dencausse A; Corot C
    Br J Radiol; 2008 Mar; 81(963):258-9. PubMed ID: 18270297
    [No Abstract]   [Full Text] [Related]  

  • 20. Neurotoxicity of contrast media for magnetic resonance imaging after generalized breakdown of the blood-brain barrier.
    Evill CA; Wilson AJ; Fletcher MC; Sage MR
    Acad Radiol; 1996 Aug; 3 Suppl 2():S336-8. PubMed ID: 8796597
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.